Korean J Pain 2021; 34(1): 4-18
Published online January 1, 2021 https://doi.org/10.3344/kjp.2021.34.1.4
Copyright © The Korean Pain Society.
1Department of Anesthesia and Pain Medicine, Pusan National University School of Medicine, Yangsan, Korea
2Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence to:Kyung-Hoon Kim
Pain Clinic, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea
Handling Editor: Francis S. Nahm
Received: November 30, 2020; Revised: December 15, 2020; Accepted: December 22, 2020
Except for carbamazepine for trigeminal neuralgia, gabapentinoid anticonvulsants have been the standard for the treatment of neuropathic pain. Pregabalin, which followed gabapentin, was developed with the benefit of rapid peak blood concentration and better bioavailability. Mirogabalin besylate (DS-5565, Tarlige®) shows greater sustained analgesia due to a high affinity to, and slow dissociation from, the α2δ-1 subunits in the dorsal root ganglion (DRG). Additionally, it produces a lower level of central nervous system-specific adverse drug reactions (ADRs), due to a low affinity to, and rapid dissociation from, the α2δ-2 subunits in the cerebellum. Maximum plasma concentration is achieved in less than 1 hour, compared to 1 hour for pregabalin and 3 hours for gabapentin. The plasma protein binding is relatively low, at less than 25%. As with all gabapentinoids, it is also largely excreted via the kidneys in an unchanged form, and so the administration dose should also be adjusted according to renal function. The equianalgesic daily dose for 30 mg of mirogabalin is 600 mg of pregabalin and over 1,200 mg of gabapentin. The initial adult dose starts at 5 mg, given orally twice a day, and is gradually increased by 5 mg at an interval of at least a week, to 15 mg. In conclusion, mirogabalin is anticipated to be a novel, safe gabapentinoid anticonvulsant with a greater therapeutic effect for neuropathic pain in the DRG and lower ADRs in the cerebellum.
Keywords: Analgesia, Anticonvulsants, Ataxia, Calcium Channels, Cerebellum, Dizziness, Gabapentin, Ganglia, Spinal, Mirogabalin, Neuralgia, Pregabalin, Sleepiness.
Other than the use of carbamazepine in treating trigeminal neuralgia, gabapentinoids have become the standard drugs in treating neuropathic pain. There are 2 calcium channels in the human body: voltage-gated calcium channels (VGCCs) and ligand-gated (receptor-operated) calcium channels. The mechanism of relief for neuropathic pain is strongly related to the α2δ ligands which bind to the α2δ subunits of VGCCs non-specifically.
VGCCs are usually made up of the main pore-forming α1 subunit and auxiliary subunits, including the β and α2δ, or sometimes γ subunits. Four α2δ (α2δ-1, α2δ-2, α2δ-3, and α2δ-4) subunit genes have been cloned. The α2δ-1 subunit is widely distributed in the skeletal, smooth, and cardiac muscles, as well as the central and peripheral nervous systems, and endocrine tissues. Cardiac dysfunction or neuropathic pain is the representative pathologic condition with an α2δ-1 subunit disorder. The α2δ-2 subunit is principally located in the central nervous system, especially the cerebellum. Pathology in the α2δ-2 subunit may exhibit itself as epilepsy or cerebellar ataxia .
Therefore, conventional gabapentinoids, gabapentin and pregabalin, bind to the α2δ-1 and α2δ-2 subunits nonselectively, and produce unwanted adverse drug reactions (ADRs) in the central nervous system, such as dizziness, ataxia, somnolence, and headache. A novel gabapentinoid anticonvulsant needs selectivity for the α2δ subunits for increasing its therapeutic effect for neuropathic pain via the α2δ-1 subunits, and for decreasing central ADRs through the α2δ-2 subunits.
Mirogabalin besylate (DS-5565, Tarlige®; Daiichi Sankyo Company Limited, Tokyo, Japan), which selectively binds to and modulates the α2δ-1 subunits of VGCCs, was recently approved for manufacturing and marketing for treatment of peripheral neuropathic pain in Japan on January 8, 2019, after completing phase 3 clinical trials on patients with diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). While the drug has received approval for use in Japan, it is still awaiting approval in other countries. Tablets with various doses of mirogabalin besylate are available, including 2.5, 5, 10, and 15 mg. The initial recommended dose for adults starts from 5 mg, given orally twice a day. The dose is slowly increased by 5 mg, at an interval of at least a week, to 15 mg [2,3].
Following studies focusing on selectivity, celecoxib (Celebrex®; Pfizer, New York, NY), a selective cyclooxygenase 2 inhibitor non-steroidal antiinflammatory drug (NSAID), or oliceridine (Olinvo®; Trevena Inc., King of Prussia, PA), a μ-receptor G protein pathway selective modulator opioid, has been used or developed for increasing therapeutic effects, while decreasing ADRs .
This review examines expectations for mirogabalin, as a novel ligand of the α2δ-1 subunits (compared to the α2δ-2 subunits) containing VGCCs.
The current trends in development of novel drugs focus on target selectivity, rather than polypharmacy, for achieving increased therapeutic effects, but decreased ADRs . A novel gabapentinoid, mirogabalin, has been introduced for treatment of neuropathic pain, including DPNP and PHN in 2019, highlighting its higher selective binding affinity/slow dissociation half-life to the α2δ-1 rather than the α2δ-2 subunit. However, while, like pregabalin, it showed greater selective binding affinity to the α2δ-1 than to the α2δ-2 subunit, it showed a markedly slower dissociation rate from α2δ-1 compared to α2δ-2, in a human and rat study .
Calcium channels can be divided into voltage- and ligand-gated channels. The VGCCs, which open when the membrane potential is changed, include 1) high threshold-activated channels: (1) L [long-lasting or dihydropyridine (DHP), Cav1.1, and 1.2]-, (2) P/Q (Purkinje/question Cav2.1)-, and (3) N (neural, Cav2.2)-type, 2) intermediate threshold-activated channels: Cav1.3, Cav1.4, and R (residual, Cav2.3)-type channels, and 3) low threshold-activated channels: T (transient, Cav3.1, 3.2, and 3.3)-type channels [7,8]. However, the ligand-gated calcium channels, which are activated by ligands binding, include the inositol 1,4,5-triphosphate (Ins3P or IP3) receptors, ryanodine receptors, two-pore channels, cation channels of the sperm, and store-operated channels (Table 1) .
Among the Cav1 family (L-type channels), Cav1.1 (α1S subunit) is located in the skeletal muscle, while Cav1.2 (α1C subunit) is found mainly in the cardiac muscle and neurons. Cav1.3 (α1D subunit) has a role in neurotransmission in auditory cells and pacemaker activity, and Cav1.4 (α1F subunit) acts on synaptic transmission in the retina [7,8].
The VGCCs contain 5 different subunits: α1 (170-240 kDa), α2 (150 kDa), β (50-78 kDa), δ (17-25 kDa), and γ (32 kDa) in stoichiometric amounts [7,8,10]. The main pore-forming α1 subunit is bonded non-covalently to the auxiliary α2, β, and δ subunits, as well as to calmodulin, which modulates the calcium ion trafficking and biophysical properties of the main α1 subunit [9,10].
The pore-forming α1 subunit has 24 transmembrane α-helices, making 4 homogenous repeats (I-IV). The 4th transmembrane segment (S4) of each repeat has 5 positively charged amino acids with the 1st, 2nd, and 3rd segments (S1, S2, and S3) producing the voltage-sensing domain of the channel. There are pore loops present between the 5th and 6th segments (S5 and S6). There are also loops between I (S6) and II (S1), II (S6) and III (S1), and III (S6) and IV (S1) (Fig. 1) [9,11].
The α2, δ, and β subunits are located extracellularly, in the membrane, and intracellularly, respectively.
The intracellular (cytosolic) β subunits are composed of an Src homology (SH3) domain and a guanylate kinase (GK) domain. The GK domain binds to the intracellular linker between domains I and II of the α1 subunit. The membrane-anchored α2δ subunit consists of the extracellular α2 and membrane-associated δ subunits. They are connected with a disulfide bond (Fig. 1) [9,11].
The membrane (glycosylphosphatidylinositol, GPI)-anchored α2δ subunit is tasked with modulation of the calcium channel current kinetics, and with increasing trafficking of the channel to the membrane. The α2δ subunit determines VGCC abundance in the presynaptic terminals, and configures synaptic VGCCs to drive exocytosis through an extracellular metal ion-dependent adhesion site (MIDAS), a conserved set of amino acids with the predicted von Willebrand A (VMA) domain of the α2δ subunit .
At least 4 α2δ subunit genes are cloned: ① The α2δ-1 subunit mRNA was cloned from skeletal muscle (Cav1.1); however, it is found throughout the human body, including the cardiac and smooth muscles associated with Cav1.2. It is also found in many neuronal cell types and the dorsal root ganglia (DRGs), especially in excitatory rather than inhibitory interneurons. ② The α2δ-2 subunit mRNA is found mainly in the brain (such as the Purkinje cells in the cerebellum, medulla, hippocampus, and striatum) or in the lungs. ③ The α2δ-3 subunit mRNA is found in the brain (cerebral cortex, caudate-putamen, and hippocampus), heart, and skeletal muscle. ④ The recently identified α2δ-4 subunits are distributed in the non-neuronal tissues, such as the adrenal or pituitary glands. The human α2δ-4 protein sequence shares 30%, 32%, and 61% of its identity with human α2δ-1, α2δ-2, and α2δ-3, respectively. The α2δ-4 subunits are located in the retina, therefore, they are deeply related to night blindness [1,13].
Gabapentin and pregabalin bind to the α2δ-1 and α2δ-2 subunits, especially, to the 3rd arginine (R, rectus) in the RRR motif, which is located N-terminal to the VMA domain. The α2δ-1 subunit plays a role in development of chronic neuropathic pain, and is the target for treatment. The α2δ-2 subunit is concentrated in the Purkinje cells of the cerebellum, and this explains why the conventional gabapentinoid anticonvulsants present the representative ADRs, such as dizziness and ataxia (Fig. 1) .
In general, mechanisms of action for gabapentinoids include: (1) Gabapentinoids inhibit forward (anterograde) trafficking of α2δ-1 (from the endoplasmic reticulum through the Golgi complex to the cell membrane) intracellularly. (2) They inhibit Rab-11-dependent final recycling of endosomal VGCCs intracellularly, resulting in reduced excitatory neurotransmitter release in the synapse. (3) They inhibit thrombospondin (TSP, extracellular matrix protein)-mediated processes extracellularly, resulting in reducing excitatory synaptogenesis. (4) They stimulate glutamate uptake by excitatory amino acid transporters extracellularly. (5) Minor mechanisms related to gabapentinoids may include inhibition of descending serotonergic facilitation, stimulation of descending inhibition, anti-inflammatory effect, and influence on the affective component of pain  (Fig. 1).
The α2δ-1 and β subunits in the DRGs mediate forward trafficking of calcium channels (exocytosis) to the dorsal horn from the endoplasmic reticulum which is facilitated by protein kinase C (PKC) through the Golgi complex to the cell membrane .
Gabapentinoids act on the DRGs and A nerve fibers, especially medium-sized neurons associated with Aδ nerve fibers and small isolectin B4 (IB4)-negative DRGs, projecting to the excitatory neurons in the lamina I and II of the spinal dorsal horn (compared to large neurons associated with Aβ nerve fibers and IB4-positive neurons, projecting to the inhibitory neurons) .
The α2δ-1 and β subunits of the VGCCs mediate forward trafficking of the calcium channels from the endoplasmic reticulum, facilitated by PKC. The reduced recycling of endosomal VGCCs leads to a reduced calcium channel expression and decreased transmitter release at the synaptic membrane. Gabapentinoids inhibit Rab-11 (master regulators of the surface expression of receptors and adhesion protein)-dependent recycling of endosomal VGCCs. In addition, TSP 4 (a family of 5 extracellular matrix oligomeric glycoproteins) mediates excitatory synaptogenesis with cellular migration, attachment, and cytoskeletal dynamics. It also mediates the binding to the α2δ-1 subunits. However, gabapentin does not seem to target TSPs/α2δ-1 directly [15,16].
On the other hand, 2 systems for intracellular calcium extrusion include the plasma membrane Ca2+ ATPase (PMCA) and plasma membrane Na+/Ca2+ exchanger (NCX). The NCX has a low calcium affinity but a high capacity for calcium transport, whereas the PMCA has the opposite properties .
Gabapentinoids, including gabapentin and pregabalin, have become the drugs of choice for the treatment of neuropathic pain with positive symptoms .
Binding affinity is measured by the equilibrium dissociation constant (Kd). The smaller the Kd value, the greater the binding affinity of the ligand for its target. Gabapentin is known to bind to α2δ subunits with greater affinity for α2δ-1 (Kd = 59 nmol/L) compared to α2δ-2 (Kd = 153 nmol/L) .
Pregabalin also shows greater affinity to the α2δ-1 (Kd = 62.5 nmol/L) compared to the α2δ-2 (Kd = 125.0 nmol/L). Mirogabalin similarly exhibits greater affinity to the α2δ-1 (Kd = 13.5 nmol/L), compared to the α2δ-2 (Kd = 22.7 nmol/L). However, pregabalin show similar dissociation time from the α2δ-1 [Koff = 0.5051 per hour] and the α2δ-2 [Koff = 0.5103 per hour]. Mirogabalin exhibits slow dissociation from the α2δ-1 [Koff = 0.0627 per hour] compared to the α2δ-2 [Koff = 0.2837 per hour]. Its dissociation half-life is also longer from the α2δ-1 (t1/2 = 11.1 per hour) than the α2δ-2 (t1/2 = 2.4 per hour) .
Therefore, mirogabalin, compared with pregabalin, has a similar degree of greater affinity to the α2δ-1 compared to the α2δ-2, however, its dissociation time from the α2δ-1, compared to the α2δ-2, is longer than with pregabalin. The secret is that mirogabalin, compared to pregabalin, shows a greater therapeutic analgesic effect for neuropathic pain and lesser ADRs due to the slow dissociation from the α2δ-1 subunits, not due to the binding affinity to the α2δ-1 subunits. Mirogabalin has a longer dissociation half-life from the α2δ-1 subunits than the α2δ-2 subunits, in contrast to pregabalin.
In conclusion, mirogabalin has a high affinity to and slow dissociation from the α2δ-1 subunits in the DRGs, producing greater therapeutic effects; it also has a low affinity to and fast dissociation from the α2δ-2 subunits in the cerebellum, producing lesser ADRs.
Thirty-eight studies related to mirogabalin had been published prior to October 15, 2020 when searching PubMed. The mirogabalin studies include 8 review articles, 22 clinical trials, 2 case reports, and 6 animal studies (Table 2).
From the 8 review articles, mirogabalin was suitable for the treatment of peripheral neuropathic pain, especially DPNP and PHN [2,3,18]. It is expected to become the 4th United States Food and Drug Administration (U.S. FDA)-approved drug for DPNP, along with pregabalin, duloxetine, and tapentadol . It showed a superior result to pregabalin in the average daily pain score, with manageable ADRs (fatigue, dizziness, sedation, somnolence, ataxia, weight gain, and edema) for DPNP [20,21].
However, it showed a negative result with fibromyalgia [from the pain in patients with fibromyalgia (a very large, multicenter program made by three, randomized, double-blind, placebo and active-controlled (pregabalin), 13-week studies, evaluating mirogabalin for the treatment of pain associated with fibromyalgia, aged 18 years or older, ALDAY) study] .
Relatively clear mechanisms of action for mirogabalin, related to binding affinity and dissociation rates to the α2δ-1 and α2δ-2 subunits of VGCCs, especially in the DRG and cerebellum have been introduced [6,23].
For healthy volunteers, mirogabalin, at doses up to 15 mg twice a day for 7 days, showed safety and tolerability with ADRs .
Mirogabalin was effective on various neuropathic pain syndromes . In patients with PHN, 10 or 15 mg of mirogabalin twice a day for 52 weeks showed effective control of pain, with mild to moderate ADRs (An Asian, phase 3, multicenter, randomized double-blind, placebo-controlled 14-week study of DS-5565 in patients with postherpetic neuralgia followed by a 52-week open-label extension, NEUCOURSE clinical trial) . All doses (15, 20, and 30 mg/d) for 14 weeks were superior to a placebo for relieving PHN . Mirogabalin 30 mg, after a 1-month cessation of pregabalin, also showed effectiveness and safety for 187 patients with PHN in Taiwan .
In patients with DPNP, mirogabalin 30 mg showed significant pain relief, compared to a placebo, in a phase 3 study (an Asian, phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of mirogabalin in patients with diabetic peripheral neuropathic pain, followed by a 52-week open-label extension, REDUCER clinical trial) in Japan, Taiwan, South Korea, and Malaysia . In a phase 2 study, the average daily pain score was reduced at a daily dose of mirogabalin of 5, 10, 15, 20, and 30 mg for 5 weeks, compared to a placebo . A similarly-designed phase 2 study showed a decreased average daily pain score and sleep interference score . In another phase 2 study, mirogabalin (5, 10, 15, 20, and 30 mg twice a day) decreased the average daily pain score, average daily sleep-interference score, and ADRs . In addition, mirogabalin 10 or 15 mg twice a day showed long-term (52 wk) safety and efficacy in patients with DPNP .
Mirogabalin (17.7 mg) was estimated to be 17-fold more potent than pregabalin (300 mg) in patients with DPNP. Twice-daily dosing of mirogabalin decreased dizziness more than once-daily dosing .
Unfortunately, mirogabalin showed a negative result. Both mirogabalin 15 mg once and twice daily did not improve the worst weekly average daily pain score at week 13 . In addition, the ALDAY phase 3 study did not decrease pain in patients with fibromyalgia .
Mirogabalin improved leg symptoms, low back pain, and sleep disturbance in patients with lumbar spine disease .
In patients with renal failure, a fixed dose of 7.5 mg once and twice a day reduced DPNP and PHN with a tolerable level of ADRs . In moderate or severe renal dysfunction, a dose reduction was needed by 50% or 70%. However, a dose adjustment was not needed in mild renal dysfunction [38,39].
In patients with mild or moderate hepatic impairment, a single 15 mg dose of mirogabalin did not produce significant ADRs .
Metformin, a biguanide antihyperglycemic agent for type 2 diabetes, is an essential drug for control of blood glucose. However, the U.S. FDA recalled some types of metformin because it may contain N-nitrosodimethylamine (NMDA), a hepatotoxic and carcinogenic organic compound, above the acceptable intake limit on October 5, 2020. Even though the use of metformin is currently reduced, it is difficult to avoid coadministration. Coadministration of metformin and mirogabalin was well-tolerated in healthy volunteers .
Probenecid, treating gout and hyperuricemia, has known interactions with some commonly-used drugs, such as non-steroidal anti-inflammatory drugs (indomethacin, ketoprofen, ketorolac, and naproxen), antibiotics (cephalosporins, quinolones, and penicillins), methotrexate, acyclovir, and lorazepam, and reduces excretion of these drugs .
Probenecid inhibits both renal and metabolic clearance; cimetidine reduces renal clearance. Even though renal excretion of a single oral dose of mirogabalin 15 mg in healthy volunteers was slightly decreased with coadministration of both probenecid 500 mg and cimetidine 400 mg, adjustment of the dose of mirogabalin was not recommended clinically in a phase 1 study .
Peak plasma mirogabalin concentration decreased by 28% following tramadol coadministration, but increased by 20% following ethanol coadministration. Coadministration with either lorazepam or ethanol increased pharmacodynamic parameters. In addition, mirogabalin/lorazepam and mirogabalin/zolpidem increased sleepiness. Mirogabalin/tramadol and mirogabalin/ethanol increased incidence of nausea and headache, respectively .
Fed (high-fat meal) or fasting states in healthy volunteers did not affect bioavailability after taking a single dose of mirogabalin 15 mg. No food restriction was needed when taking mirogabalin in a phase 1 study .
At supra-therapeutic doses (over 4 times the therapeutic dose), mirogabalin showed higher abuse potential than a placebo, but lower abuse potential than diazepam and pregabalin .
There have been 2 case reports. Neutropenia induced by mirogabalin 10 mg for 6 weeks was noted in patients with squamous cell carcinoma of the lung, even after cessation of coadministration of acetaminophen and mexiletine .
There was a case of trigeminal trophic syndrome (TTS) responding to mirogabalin . TTS is a rare facial ulceration which may appear after damage to the trigeminal nerve or its central sensory connections (herpes zoster or Hansen’s disease). A triad of TTS consists of anesthesia, paresthesia, and facial ulceration . It is not uncommon to use mirogabalin for the treatment of herpes zoster in the territory of the trigeminal nerve.
Six animal studies can be found in PubMed. Focused on the unique binding ability of mirogabalin and pregabalin to the α2δ-1 subunit of VGCCs, on N-type calcium channel currents of rat DRG culture neurons, they inhibit N-type calcium currents at 50 μM and 200 μM, respectively. The authors concluded that the potent and prolonged analgesic effects of mirogabalin are associated with its potent and selective binding to the α2δ-1 subunits, resulting in functional inhibition of calcium channel currents . However, it is better to understand the mechanisms of action for mirogabalin as resulting from slow dissociation from the α2δ-1 subunits in the DRGs and rapid dissociation from the α2δ-2 subunits in the cerebellum (rather than its more potent and selective binding affinity to the α2δ-1 subunits in comparison to the α2δ-2 subunits) from their previous article .
In a spinal cord injury model, established by acute compression of the spinal cord at the T6-T7 level in rats, mirogabalin showed potent and long-lasting central analgesic effects .
In a chronic constriction injury (CCI) model in rats, mirogabalin showed dose-dependent anxiety-related behavior, as well as tactile allodynia . A similar study on the anxiolytic effect of mirogabalin, by the same study group, was performed in the Sluka model (2 intramuscular injections of acid saline into the gastrocnemius muscle). A mirogabalin study showed an analgesic effect in an intermittent cold stress model in mice and Sluka model rats, suggesting effectiveness in patients with fibromyalgia . Mirogabalin alleviated anxiolytic behavior in Sluka model rats, suggesting potential to relieve anxiety in fibromyalgia . On the other hand, there was no analgesic effect in patients with fibromyalgia in the ALDAY phase 3 program and a 13-week study using mirogabalin 15 mg once or twice a day . Another anxiety-related study showed that mirogabalin protected multiple brain functions from repeated restraint stress (2 hr/day), mediated by inhibition of hippocampal neuron hyperactivation .
Available mirogabalin besylate tablets include 2.5, 5, 10, and 15 mg. The initial dose for adults without renal dysfunction is recommended starting from 5 mg, given orally twice a day. The dose is gradually increased by 5 mg, at an interval of at least a week, to 15 mg at the 3rd week [2,3,25-33].
After taking oral mirogabalin, maximum plasma concentration was achieved at 1 hour [19,39]. Its plasma protein binding was relatively low, at less than 25% . It was mostly excreted by the kidney, and underwent minimal metabolism .
According to renal function (creatinine clearance, Clcr), the administration dose of mirogabalin should be adjusted in at least 3 stages: (1) a mild degree (90 > Clcr ≥ 60 mL/m), (2) a moderate degree (60 > Clcr ≥ 30 mL/m), and (3) a severe degree (30 > Clcr mL/m) of renal dysfunction. In mild renal dysfunction, the initial dose starts from 5 mg twice a day, slowly increased by 5 mg at an interval of 1 week, to 15 mg. In moderate renal dysfunction, the initial dose starts from 2.5 mg twice a day, slowly increased by 2.5 mg at an interval of 1 week, to 7.5 mg twice a day. In severe renal dysfunction, the initial dose starts from 2.5 mg once a day, slowly increased by 2.5 mg at an interval of 1 week, to 7.5 mg once a day (Table 3) .
A dose reduction of mirogabalin is suggested by 50% and 75% in patients with moderate and severe renal dysfunction, respectively [19,38]. A single dose of mirogabalin 5 mg was tolerable in patients with various degree of renal failure, however, a dose adjustment should be considered in patients with severe degree and end-stage renal failure .
In a mild or moderate hepatic dysfunction, a single dose of mirogabalin 15 mg was also tolerable .
Mirogabalin binds to and dissociates from the α2δ subunits. Its binding ability is stronger for α2δ-1 than for α2δ-2 subunits. It also dissociates from the α2δ-1 subunits more slowly than the α2δ-2 subunits . Therefore, it showed a potent and long-lasting binding to the α2δ-1 subunits, which exhibited a therapeutic analgesic effect through the DRGs, and a low incidence of ADRs through the cerebellum due to weak and shorting-lasting binding to the α2δ-2 subunits, with a wide safety index (a broad therapeutic window).
In a streptozotocin-induced diabetic model in rats, an effective analgesic dose (ED50) of mirogabalin was 4 times lower than that of pregabalin. The effective dose for central nervous system ADRs (ED50) occurs at about double the analgesic dose (ED50) in the Rotarod performance test, and at 10 times the analgesic dose (ED50) in a locomotor activity test. The safety index (effective ADR dose/effective analgesic dose) of mirogabalin is 2.1 and 10.0, compared to 0.4 and 4.2 for pregabalin, in the Rotarod performance and the locomotor activity test, respectively .
The most common ADRs in the 277 patients with DPNP developed in the nervous system (28.0%), such as dizziness (9.4%), somnolence (6.1%), headache (6.1%), and balance disorder (0.5%). Gastrointestinal ADRs (13.7%) included constipation (4.3%), nausea (4.0%), diarrhea (2.9%), and vomiting (2.9%). Generalized ADRs (13%) included peripheral edema (4.7%), fatigue (3.6%), weight gain (1.8%), urinary tract infection (2.9%), hyperglycemia (2.2%), and fall (1.4%) .
Mirogabalin 30 mg showed similar pain relief, number needed to treat (NNT), and a slightly lower incidence of withdrawal ADRs, compared with pregabalin 600 mg, gabapentin over 1,200 mg, and duloxetine 60 mg .
Maladaptation and dysregulation of the α2δ-1 subunits of VGCCs may cause neuropathic pain . Mirogabalin has a strong binding affinity to and slow dissociation property from α2δ-1 in the DRGs of the spinal cord, exhibiting a potent and prolonged analgesic therapeutic effect. It also has an weak binding affinity to and fast dissociation property from α2δ-2 in the Purkinje fibers of the cerebellum, exhibiting weak and short-lasting ADRs.
The starting dose is 5 mg twice a day in the 1st week, escalating to 10 mg in the 2nd week, and finally achieving a dose of 15 mg in the 3rd week. Dose adjustment is needed in patients with renal dysfunction. An equianalgesic daily dose for gabapentin over 1,200 mg or pregabalin 600 mg is mirogabalin 30 mg. Food restriction is not needed. Tramadol decreases a peak concentration of mirogabalin, while ethanol increases it. Lorazepam or ethanol increases the pharmacodynamic effects of mirogabalin. Coadministration of lorazepam or zolpidem increases somnolence. Tramadol increases nausea and ethanol increases headache in patients taking mirogabalin.
A progression from gabapentin to pregabalin originated from its rapid peak in blood concentration (3 hr to 1 hr) resulting from an increased absorption area expanding from the small intestine into the ascending colon, resulting in linear absorption . Even though it is indicated for PHN and DPNP currently, it is also available for all types of central and peripheral neuropathic pain.
Jae-Yeon Kim: Writing/manuscript preparation; Salahadin Abdi: Data curation; Billy Huh: Resources; Kyung-Hoon Kim: Writing/manuscript preparation.
No potential conflict of interest relevant to this article was reported.
This study was supported by a 2-year research grant from Pusan National University (2019-2021).